Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
LAGEVRIO (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
LAGEVRIO
Date registered
Evaluation commenced
Decision date
Approval time
104 (255 working days)
Active ingredients
molnupiravir
Registration type
NCE/NBE
Indication
LAGEVRIO (capsule) has provisional approval for the treatment of adults with COVID-19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk for hospitalisation or death (see section 5.1 Pharmacodynamic properties - clinical trials).
The decision to approve this indication has been made on the basis of the analysis of efficacy and safety data from a Phase 3 trial. Continued approval of this indication depends on additional data.